Protara Therapeutics (TARA) Current Deferred Revenue (2013)
Protara Therapeutics (TARA) posted quarterly Current Deferred Revenue of $2.9 million for Q4 2013.
Protara Therapeutics (TARA) Current Deferred Revenue (2013) Analysis & Trends
Protara Therapeutics (TARA) has reported Current Deferred Revenue for 1 consecutive years, with $2.9 million the latest figure, recorded in Q4 2013.
- In Q4 2013, Current Deferred Revenue changed N/A year-over-year to $2.9 million; the TTM figure through Dec 2013 stood at $2.9 million (changed N/A YoY), while the FY2013 annual figure was $2.9 million, changed N/A from the prior year.
- Current Deferred Revenue held at $2.9 million in Q4 2013 per TARA's latest filing.
- Across five years, Current Deferred Revenue topped out at $2.9 million in Q4 2013 and bottomed at $2.9 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 2.95 Mn |